Autologous Mitochondrial Transplant for Cerebral Ischemia During Standard Endovascular Reperfusion Therapy

What this Trial Is About

Stroke is a leading cause of disability and death worldwide, with more than 80% of cases caused by blocked blood flow to the brain, which leads to cell death. Researchers are investigating whether infusing healthy mitochondria—tiny energy-producing parts of cells—into brain vessels during standard treatment can help reverse damage caused by this lack of blood flow. This study is the first to test this approach in human brains, building on previous animal studies and heart trials that showed safety and potential benefits. The study involves patients who are undergoing standard endovascular reperfusion therapy to restore blood flow after cerebral ischemia. During this procedure, a small muscle biopsy will be taken near the surgical site to extract the patient's own mitochondria. These healthy mitochondria will then be infused directly into the brain artery through a microcatheter as part of the ongoing reperfusion treatment, without interrupting the standard care. Participants will be monitored closely for safety during and after the mitochondrial infusion, including checks for severe adverse events related to the infusion or muscle biopsy up to seven days post-procedure. Researchers will also assess the reduction in brain tissue damage after the treatment. The total study participation includes the procedure and follow-up safety monitoring, aiming to confirm the safety and feasibility of this novel mitochondrial transplant during brain ischemia treatment.

Autologous Mitochondrial Transplant for Cerebral Ischemia